Determine the efficacy and safety of COVID19-0001-USR in the treatment of SARS-COV-2 infection in mild to moderate manifestations administered via nebulization/inhalation.
This is an interventional, randomized controlled, double-blind study (i.e., active and passive control), 1 intervention group will be randomized with COVID 19-001-USR, and a control group to receive a placebo intervention to assess efficacy, tolerance, and decrease viral load and clinical manifestation on patients infected with SARS-COV-2. This will be a self-administered study drug 3 times a day for 7 days
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2
0.9% NS via nebulization
Cimedical
Barranquilla, Atlántico, Colombia
RECRUITINGChange on viral load results from baseline after using COVID19-0001-USR via nebulization
COVID19-0001-USR 1% nebulized pathway changes viral load of SARS-COV-2 virus (COVID19) in the upper and lower airways if started during the initial phase of infection
Time frame: Treatment Period of 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.